For more information, get Portfolio Grader’s complete analysis of CCLP stock. Louis Navellier ... from InvestorPlace Media, http://investorplace.com/2016/05/5-stocks-with-poor-earnings-revisions-fve-rlgt-cdi-cytx-cclp/.
The company now expects full year contract revenue to range between $275 million and $283 million, up from its prior outlook of $ ... events. CYTX closed Tuesday's trading at $2.10, down 0.47%. In after-hours, the stock was down …
Sign-up for a FREE trial here. Summit Materials, Inc. (NYSE: SUM announced the pricing of a secondary offering of 16,614,949 shares of Class A common stock by certain selling stockholders, including affiliates of The Blackstone …
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), …